Literature DB >> 25795758

IFN-α/β receptor signaling promotes regulatory T cell development and function under stress conditions.

Amina Metidji1, Sadiye Amcaoglu Rieder2, Deborah Dacek Glass2, Isabelle Cremer3, George A Punkosdy2, Ethan M Shevach4.   

Abstract

Type I IFNs are a family of cytokines with antiviral and immunomodulatory properties. Although the antiviral effects of IFNs are well characterized, their immunomodulatory properties are less clear. To specifically address the effects of type I IFNs on T regulatory cells (Tregs), we studied mixed bone marrow chimeras between wild-type and IFN-α/β receptor (<span class="Gene">IFNAR) knockout (KO) mice, and heterozygous female mice expressing a Treg-specific deletion of the IFNAR. In these two models, IFNAR signaling promotes the development of the Treg lineage in the thymus and their survival in the periphery. IFNAR KO Tregs had a higher expression of the proapoptotic gene Bim and higher frequency of active caspase-positive cells. IFNAR KO Tregs from chimeric mice displayed a more naive phenotype, accompanied by lower levels of CD25 and phosphorylated STAT5. Therefore, in Tregs, IFNAR signaling may directly or indirectly affect phosphorylation of STAT5. In mixed chimeras with Scurfy fetal liver, Tregs derived from IFNAR KO bone marrow were unable to control T effector cell activation and tissue inflammation. Under stress conditions or in a competitive environment, IFNAR signaling may be required to maintain Treg homeostasis and function.
Copyright © 2015 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25795758      PMCID: PMC4402260          DOI: 10.4049/jimmunol.1500036

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  48 in total

1.  FoxP3+ T cells undergo conventional first switch to lymphoid tissue homing receptors in thymus but accelerated second switch to nonlymphoid tissue homing receptors in secondary lymphoid tissues.

Authors:  Jee H Lee; Seung G Kang; Chang H Kim
Journal:  J Immunol       Date:  2007-01-01       Impact factor: 5.422

Review 2.  IRFs: master regulators of signalling by Toll-like receptors and cytosolic pattern-recognition receptors.

Authors:  Kenya Honda; Tadatsugu Taniguchi
Journal:  Nat Rev Immunol       Date:  2006-09       Impact factor: 53.106

Review 3.  Type I interferons in host defense.

Authors:  Daniel B Stetson; Ruslan Medzhitov
Journal:  Immunity       Date:  2006-09       Impact factor: 31.745

Review 4.  The BCL-2 protein family: opposing activities that mediate cell death.

Authors:  Richard J Youle; Andreas Strasser
Journal:  Nat Rev Mol Cell Biol       Date:  2008-01       Impact factor: 94.444

5.  Antiapoptotic Mcl-1 is critical for the survival and niche-filling capacity of Foxp3⁺ regulatory T cells.

Authors:  Wim Pierson; Bénédicte Cauwe; Antonia Policheni; Susan M Schlenner; Dean Franckaert; Julien Berges; Stephanie Humblet-Baron; Susann Schönefeldt; Marco J Herold; David Hildeman; Andreas Strasser; Philippe Bouillet; Li-Fan Lu; Patrick Matthys; Antonio A Freitas; Rita J Luther; Casey T Weaver; James Dooley; Daniel H D Gray; Adrian Liston
Journal:  Nat Immunol       Date:  2013-07-14       Impact factor: 25.606

6.  Direct stimulation of T cells by type I IFN enhances the CD8+ T cell response during cross-priming.

Authors:  Agnes Le Bon; Vanessa Durand; Elisabeth Kamphuis; Clare Thompson; Silvia Bulfone-Paus; Cornelia Rossmann; Ulrich Kalinke; David F Tough
Journal:  J Immunol       Date:  2006-04-15       Impact factor: 5.422

7.  Persistent LCMV infection is controlled by blockade of type I interferon signaling.

Authors:  John R Teijaro; Cherie Ng; Andrew M Lee; Brian M Sullivan; Kathleen C F Sheehan; Megan Welch; Robert D Schreiber; Juan Carlos de la Torre; Michael B A Oldstone
Journal:  Science       Date:  2013-04-12       Impact factor: 47.728

8.  Type I IFNs regulate effector and regulatory T cell accumulation and anti-inflammatory cytokine production during T cell-mediated colitis.

Authors:  Abhisake Kole; JianPing He; Aymeric Rivollier; Danielle D Silveira; Kazuya Kitamura; Kevin J Maloy; Brian L Kelsall
Journal:  J Immunol       Date:  2013-08-02       Impact factor: 5.422

9.  Type I interferons keep activated T cells alive.

Authors:  P Marrack; J Kappler; T Mitchell
Journal:  J Exp Med       Date:  1999-02-01       Impact factor: 14.307

10.  CCR7 provides localized access to IL-2 and defines homeostatically distinct regulatory T cell subsets.

Authors:  Kate S Smigiel; Elizabeth Richards; Shivani Srivastava; Kerri R Thomas; Jan C Dudda; Kimberly D Klonowski; Daniel J Campbell
Journal:  J Exp Med       Date:  2013-12-30       Impact factor: 14.307

View more
  32 in total

Review 1.  Tolerogenic vaccines: Targeting the antigenic and cytokine niches of FOXP3+ regulatory T cells.

Authors:  Mark D Mannie; Kayla B DeOca; Alexander G Bastian; Cody D Moorman
Journal:  Cell Immunol       Date:  2020-07-15       Impact factor: 4.868

Review 2.  Type I interferon signaling, regulation and gene stimulation in chronic virus infection.

Authors:  Sabelo Lukhele; Giselle M Boukhaled; David G Brooks
Journal:  Semin Immunol       Date:  2019-05-30       Impact factor: 11.130

3.  Eos Is Redundant for Regulatory T Cell Function but Plays an Important Role in IL-2 and Th17 Production by CD4+ Conventional T Cells.

Authors:  Sadiye Amcaoglu Rieder; Amina Metidji; Deborah Dacek Glass; Angela M Thornton; Tohru Ikeda; Bruce A Morgan; Ethan M Shevach
Journal:  J Immunol       Date:  2015-06-10       Impact factor: 5.422

4.  Barrier regulation: tolerance stops at cell death.

Authors:  Johanna Pott; Kevin J Maloy; Ana Izcue
Journal:  Nat Immunol       Date:  2016-04       Impact factor: 25.606

5.  IFN-β Facilitates Neuroantigen-Dependent Induction of CD25+ FOXP3+ Regulatory T Cells That Suppress Experimental Autoimmune Encephalomyelitis.

Authors:  Duncheng Wang; Debjani Ghosh; S M Touhidul Islam; Cody D Moorman; Ashton E Thomason; Daniel S Wilkinson; Mark D Mannie
Journal:  J Immunol       Date:  2016-09-12       Impact factor: 5.422

6.  Type I IFN signaling in T regulatory cells modulates chemokine production and myeloid derived suppressor cells trafficking during EAE.

Authors:  Shalini Tanwar; Cihan Oguz; Amina Metidji; Eric Dahlstrom; Kent Barbian; Kishore Kanakabandi; Lydia Sykora; Ethan M Shevach
Journal:  J Autoimmun       Date:  2020-07-22       Impact factor: 7.094

7.  Integration of mechanistic immunological knowledge into a machine learning pipeline improves predictions.

Authors:  Anthony Culos; Amy S Tsai; Natalie Stanley; Martin Becker; Mohammad S Ghaemi; David R McIlwain; Ramin Fallahzadeh; Athena Tanada; Huda Nassar; Camilo Espinosa; Maria Xenochristou; Edward Ganio; Laura Peterson; Xiaoyuan Han; Ina A Stelzer; Kazuo Ando; Dyani Gaudilliere; Thanaphong Phongpreecha; Ivana Marić; Alan L Chang; Gary M Shaw; David K Stevenson; Sean Bendall; Kara L Davis; Wendy Fantl; Garry P Nolan; Trevor Hastie; Robert Tibshirani; Martin S Angst; Brice Gaudilliere; Nima Aghaeepour
Journal:  Nat Mach Intell       Date:  2020-10-12

8.  Combined OX40L and mTOR blockade controls effector T cell activation while preserving Treg reconstitution after transplant.

Authors:  Victor Tkachev; Scott N Furlan; Benjamin Watkins; Daniel J Hunt; Hengqi Betty Zheng; Angela Panoskaltsis-Mortari; Kayla Betz; Melanie Brown; John B Schell; Katie Zeleski; Alison Yu; Ian Kirby; Sarah Cooley; Jeffrey S Miller; Bruce R Blazar; Duncan Casson; Phil Bland-Ward; Leslie S Kean
Journal:  Sci Transl Med       Date:  2017-09-20       Impact factor: 17.956

9.  Blocking IFNAR1 inhibits multiple myeloma-driven Treg expansion and immunosuppression.

Authors:  Yawara Kawano; Oksana Zavidij; Jihye Park; Michele Moschetta; Katsutoshi Kokubun; Tarek H Mouhieddine; Salomon Manier; Yuji Mishima; Naoka Murakami; Mark Bustoros; Romanos Sklavenitis Pistofidis; Mairead Reidy; Yu J Shen; Mahshid Rahmat; Pavlo Lukyanchykov; Esilida Sula Karreci; Shokichi Tsukamoto; Jiantao Shi; Satoshi Takagi; Daisy Huynh; Antonio Sacco; Yu-Tzu Tai; Marta Chesi; P Leif Bergsagel; Aldo M Roccaro; Jamil Azzi; Irene M Ghobrial
Journal:  J Clin Invest       Date:  2018-05-14       Impact factor: 14.808

10.  Osteopontin Promotes Protective Antigenic Tolerance against Experimental Allergic Airway Disease.

Authors:  Themis Alissafi; Evangelia Kourepini; Davina C M Simoes; Nikolaos Paschalidis; Maria Aggelakopoulou; Tim Sparwasser; Louis Boon; Hamida Hammad; Bart N Lambrecht; Vily Panoutsakopoulou
Journal:  J Immunol       Date:  2018-01-12       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.